[COVID-19: a cardiological point-of-view]

Dtsch Med Wochenschr. 2020 Jul;145(15):1063-1067. doi: 10.1055/a-1164-4161. Epub 2020 Jul 30.
[Article in German]

Abstract

The SARS-CoV-2 pandemic has rapidly spread around the world and has led to a substantial morbidity and mortality in many countries. Although Corona Virus Disease 19 (COVID-19) is primarily a respiratory tract infection, there is growing evidence that other organs including the cardiovascular system are affected by COVID-19. In this review, we summarize the association of myocardial injury with in-hospital mortality of COVID-19 patients. Furthermore, we discuss potential mechanisms of myocardial injury including myocarditis and vascular thrombosis. Last, we review the current evidence on drugs which have been evaluated or are currently tested for the treatment of COVID-19 patients.

MeSH terms

  • Adenosine Monophosphate / adverse effects
  • Adenosine Monophosphate / analogs & derivatives
  • Adenosine Monophosphate / therapeutic use
  • Alanine / adverse effects
  • Alanine / analogs & derivatives
  • Alanine / therapeutic use
  • Antiviral Agents / adverse effects
  • Antiviral Agents / therapeutic use
  • Arteritis
  • Betacoronavirus*
  • COVID-19
  • Cardiovascular Diseases / virology*
  • Coronavirus Infections / complications*
  • Coronavirus Infections / drug therapy
  • Coronavirus Infections / physiopathology
  • Humans
  • Pandemics
  • Pneumonia, Viral / complications*
  • Pneumonia, Viral / drug therapy
  • Pneumonia, Viral / physiopathology
  • SARS-CoV-2
  • Venous Thrombosis

Substances

  • Antiviral Agents
  • remdesivir
  • Adenosine Monophosphate
  • Alanine